Caristo's Latest Advancement in Heart Disease Detection
Caristo Diagnostics has made significant strides in the field of heart disease detection. The American Medical Association (AMA) has assigned important CPT codes, specifically 0992T and 0993T, to Caristo's CaRi-Heart, an AI-driven tool designed for a detailed analysis of perivascular fat and cardiovascular risk. These developments have been documented in the most recent 2026 CPT Codebook.
Understanding the Importance of CPT Codes
Current Procedural Terminology (CPT) codes play a crucial role in medical billing and accurately describing medical services. The AMA's assignment of these codes marks a pivotal point as Caristo advances toward becoming a standard component in everyday clinical practices in the United States.
Details of the Assigned CPT Codes
The newly assigned CPT codes are critical for Caristo as they continue to pursue broader clinical adoption. Here’s a brief overview of each code:
- 0992T: This code represents a noninvasive assessment of cardiac risk derived from software analysis of perivascular fat without requiring a concurrent computed tomography scan of the heart. It includes patient-specific clinical factors, with necessary interpretations provided by qualified healthcare professionals.
- 0993T: This code identifies a similar noninvasive assessment but includes a concurrent computed tomography scan of the heart. It also requires interpretation and reporting by qualified professionals.
The Path Towards U.S. Clinical Integration
With these new codes approved, Caristo is one step closer to enabling cardiologists to incorporate AI-powered coronary inflammation analysis into their routine practices. This progress aligns with the earlier decisions by the AMA's CPT Editorial Panel, which approved the use of new Category III CPT codes specifically for CaRi-Heart technology.
Innovation Through AI Technology
Caristo’s groundbreaking AI algorithms are capable of highlighting hidden risk markers associated with coronary artery disease (CAD), effectively predicting potential heart problems years ahead of conventional methods. The CaRi-Heart technology utilizes standard coronary CT angiography (CCTA) scans to assess perivascular fat, potentially unveiling hidden coronary inflammation, a critical risk factor for heart attacks. The proprietary tools, such as FAI-Score™ and CaRi-Heart Risk score, allow for personalized assessments of mortality risks, ultimately facilitating timely interventions even when other tests return normal results.
Testimonials on the Progress
Frank Cheng, CEO of Caristo Diagnostics, expressed profound optimism regarding these advancements. He stated, "This represents a huge leap forward in the battle against heart disease and underscores that AI-powered coronary inflammation analysis is essential in routine care. With the approval and assignment of these CPT codes, we’re setting the groundwork for future accessibility to precision risk assessments for at-risk individuals. This shift moves the paradigm from reactive treatments to proactive, preventive measures."
The Future of Caristo's Technology
Currently, CaRi-Heart's application is mainly focused on research purposes in the U.S. However, with the official CPT codes set to take effect on January 1, 2026, it anticipates a further push towards broader adoption in clinical settings. Aside from CaRi-Heart, Caristo also provides the CaRi-Plaque technology, which focuses on plaque and stenosis quantification. This technology has also recently been granted FDA clearance, further solidifying Caristo's role in the evolving landscape of cardiac health.
About Caristo Diagnostics
Caristo Diagnostics stands at the forefront of AI-powered heart disease detection, having originated as a spinout from the prestigious University of Oxford. The company’s innovative approach is transforming the way cardiovascular risks are identified, focusing on detecting potential issues before any significant symptoms emerge. Supported by esteemed medical institutions and researchers, Caristo is committed to revolutionizing early detection and tailored preventive measures, ultimately aiming to save lives.
Frequently Asked Questions
What are the new CPT codes assigned to Caristo's technology?
The AMA has assigned CPT codes 0992T and 0993T for Caristo's CaRi-Heart technology, enabling detailed cardiovascular risk assessment.
How does the CaRi-Heart technology work?
CaRi-Heart analyzes perivascular fat using AI from standard CT angiography scans to identify hidden risks of coronary artery disease.
When will the new CPT codes take effect?
The CPT codes for CaRi-Heart will become effective on January 1, 2026.
What is the role of AI in Caristo's technology?
AI enhances the effectiveness of CaRi-Heart by identifying subtle markers that traditional tests may miss, allowing proactive risk assessment.
What is Caristo's mission?
Caristo Diagnostics aims to revolutionize cardiovascular care through early identification of risks, enabling personalized prevention strategies.
